No matches

Educational Resources

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

Gastroenterology

20 min

expert video

Type 2 Inflammation in EoE and Impact on Disease Burden

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

Dermatology

13 min

expert video

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

Differential Diagnosis and Disease Onset in Older Adult Patients With AD

Dermatology

4 min

expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AustraliaChange country/region

Educational Resources

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

Type 2 Inflammation in EoE and Impact on Disease Burden

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

Differential Diagnosis and Disease Onset in Older Adult Patients With AD

Piecing Together the Puzzle in Patients With EoE

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care

Scientific Advances in EoE and Impact on Clinical Practice

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

Importance of Monitoring and Maintenance in EoE

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

Educational Resources

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

Type 2 Inflammation in EoE and Impact on Disease Burden

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

Differential Diagnosis and Disease Onset in Older Adult Patients With AD

Piecing Together the Puzzle in Patients With EoE

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care

Scientific Advances in EoE and Impact on Clinical Practice

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

Importance of Monitoring and Maintenance in EoE

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP